Olema Pharmaceuticals (OLMA) Total Current Liabilities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Total Current Liabilities data on file, last reported at $47.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $47.2 million, up 80.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.2 million (up 80.97% YoY), and the FY2025 annual result was $51.8 million, up 24.05% from the prior year.
• Total Current Liabilities slipped to $47.2 million in Q1 2026 per OLMA's latest filing, from $51.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $51.8 million in Q4 2025 and troughed at $10.2 million in Q1 2022.
• A 5-year average of $26.4 million and a median of $26.1 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 93.14% in 2024, then retreated 0.61% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $16.5 million in 2022, then soared by 30.65% to $21.6 million in 2023, then surged by 93.14% to $41.8 million in 2024, then advanced by 24.05% to $51.8 million in 2025, then retreated by 8.95% to $47.2 million in 2026.
• Business Quant data shows OLMA's Total Current Liabilities at $47.2 million in Q1 2026, $51.8 million in Q4 2025, and $41.7 million in Q3 2025.